Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Short term Debt (2025)

Karyopharm Therapeutics (KPTI) has disclosed Short term Debt for 1 consecutive years, with $21.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short term Debt changed N/A year-over-year to $21.0 million, compared with a TTM value of $21.0 million through Dec 2025, changed N/A, and an annual FY2025 reading of $21.0 million, changed N/A over the prior year.
  • Short term Debt was $21.0 million for Q4 2025 at Karyopharm Therapeutics, up from $12.5 million in the prior quarter.
  • Across five years, Short term Debt topped out at $21.0 million in Q4 2025 and bottomed at $6.2 million in Q2 2025.